EpiBiologics closed a $107 million Series B to advance its first‑in‑class protein‑degrading antibody programs, including lead candidate EPI‑326 targeting EGFR for non‑small cell lung and head‑and‑neck cancers. The round was co‑led by GV and Johnson & Johnson’s venture arm among other investors. The company’s EpiTAC platform uses bispecific constructs to route cell‑surface proteins for lysosomal degradation, aiming to expand the therapeutic index versus conventional inhibitors. Human testing of EPI‑326 is expected to start in the first half of 2026, with the Series B funds earmarked for IND‑enabling work and early clinical development.